BIOVF - Dosing underway for Apellis Sobi's study of pegcetacoplan in muscle weakness

Apellis Pharmaceuticals (APLS) and Swedish Orphan Biovitrum (BIOVF) having commenced dosing of the first patients in registrational Phase 2 MERIDIAN study of pegcetacoplan in ~200 adults with sporadic amyotrophic lateral sclerosis ((ALS)), a neurodegenerative disease that leads to progressive muscle weakness and paralysis.The primary endpoint is the Combined Assessment of Function and Survival rank scores at week 52.Key secondary endpoints include measures of lung function, muscle strength, and quality of life.To reduce the burden, the study has been designed to minimize the number of in-clinic visits, with approx. six clinic visits in the first year and four in second.Both the companies collaborated earlier in October, to to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy.

For further details see:

Dosing underway for Apellis, Sobi's study of pegcetacoplan in muscle weakness